Publications
505 results found
Alessi JV, Elkrief A, Ricciuti B, et al., 2023, Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: 731-743, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 5
Scheiner B, Pinato DJ, 2023, Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control., Gastroenterology, Vol: 164, Pages: 1338-1339
Chen M, Lu H, Copley SJ, et al., 2023, A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or ligand-1 inhibition immunotherapy in NSCLC, Journal of Thoracic Oncology, Vol: 18, Pages: 718-730, ISSN: 1556-0864
INTRODUCTION: Patient selection for checkpoint inhibitor immunotherapy is currently guided by programmed death-ligand 1 (PD-L1) expression obtained from immunohistochemical staining of tumor tissue samples. This approach is susceptible to limitations resulting from the dynamic and heterogeneous nature of cancer cells and the invasiveness of the tissue sampling procedure. To address these challenges, we developed a novel computed tomography (CT) radiomic-based signature for predicting disease response in patients with NSCLC undergoing programmed cell death protein 1 (PD-1) or PD-L1 checkpoint inhibitor immunotherapy. METHODS: This retrospective study comprises a total of 194 patients with suitable CT scans out of 340. Using the radiomic features computed from segmented tumors on a discovery set of 85 contrast-enhanced chest CTs of patients diagnosed with having NSCLC and their CD274 count, RNA expression of the protein-encoding gene for PD-L1, as the response vector, we developed a composite radiomic signature, lung cancer immunotherapy-radiomics prediction vector (LCI-RPV). This was validated in two independent testing cohorts of 66 and 43 patients with NSCLC treated with PD-1 or PD-L1 inhibition immunotherapy, respectively. RESULTS: LCI-RPV predicted PD-L1 positivity in both NSCLC testing cohorts (area under the curve [AUC] = 0.70, 95% confidence interval [CI]: 0.57-0.84 and AUC = 0.70, 95% CI: 0.46-0.94). In one cohort, it also demonstrated good prediction of cases with high PD-L1 expression exceeding key treatment thresholds (>50%: AUC = 0.72, 95% CI: 0.59-0.85 and >90%: AUC = 0.66, 95% CI: 0.45-0.88), the tumor's objective response to treatment at 3 months (AUC = 0.68, 95% CI: 0.52-0.85), and pneumonitis occurrence (AUC = 0.64, 95% CI: 0.48-0.80). LCI-RPV achieved statistically significant stratification of the patients into a high- and low-risk survival group (hazard ratio = 2.26, 95% CI: 1.21-4.24, p = 0.011 a
Mishra G, Majeed A, Dev A, et al., 2023, Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis, Publisher: SPRINGER, Pages: 420-432, ISSN: 1941-6628
- Author Web Link
- Cite
- Citations: 5
Fulgenzi C, D'Alessio A, Scheiner B, et al., 2023, Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy, 25th World Congress on Gastrointestinal Cancer, Publisher: ELSEVIER, Pages: S7-S7, ISSN: 0923-7534
Anpalakhan S, Huddar P, Behrouzi R, et al., 2023, Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis, FRONTIERS IN ONCOLOGY, Vol: 13, ISSN: 2234-943X
Tagliamento M, Gennari A, Lambertini M, et al., 2023, Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol: 41, Pages: 2800-+, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 4
Mostaghim A, Minkove S, Cortellini A, et al., 2023, Prior Immune Checkpoint Inhibitor Therapy in Cancer Patients Presenting With COVID-19 Was Not Associated With Worse Outcomes but Potentially Decreased COVID-19 Related Hospitalizations and Complications: Results of a Propensity-Matched Analysis Using the OnCovid International Database, International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Aldea M, Marinello A, Duruisseaux M, et al., 2023, RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion, JOURNAL OF THORACIC ONCOLOGY, Vol: 18, Pages: 576-586, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 3
Fulgenzi CAM, Scheiner B, Korolewicz J, et al., 2023, Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials, JHEP Reports, Vol: 5, Pages: 1-13, ISSN: 2589-5559
BACKGROUND & AIMS: Direct comparisons across first-line regimens for advanced hepatocellular carcinoma are not available. We performed a network metanalysis of phase III of trials to compare first-line systemic treatments for hepatocellular carcinoma in terms of overall survival (OS), progression-free survival (PFS), objective response rate, disease control rate, and incidence of adverse events (AEs). METHODS: After performing a literature review from January 2008 to September 2022, we screened 6,329 studies and reviewed 3,009 studies, leading to identification of 15 phase III trials for analysis. We extracted odds ratios for objective response rate and disease control rate, relative risks for AEs, and hazard ratios (HRs) with 95% CIs for OS and PFS, and used a frequentist network metanalysis, with fixed-effect multivariable meta-regression models to estimate the indirect pooled HRs, odds ratios, relative risks, and corresponding 95% CIs, considering sorafenib as reference. RESULTS: Of 10,820 included patients, 10,444 received active treatment and 376 placebo. Sintilimab + IBI350, camrelizumab + rivoceranib, and atezolizumab + bevacizumab provided the greatest reduction in the risk of death compared with sorafenib, with HRs of 0.57 (95% CI 0.43-0.75), 0.62 (95% CI 0.49-0.79), and 0.66 (95% CI 0.52-0.84), respectively. Considering PFS, camrelizumab + rivoceranib and pembrolizumab + lenvatinib were associated with the greatest reduction in the risk of PFS events compared with sorafenib, with HRs of 0.52 (95% CI 0.41-0.65) and 0.52 (95% CI 0.35-0.77), respectively. Immune checkpoint inhibitor (ICI) monotherapies carried the lowest risk for all-grade and grade ≥3 AEs. CONCLUSIONS: The combinations of ICI + anti-vascular endothelial growth factor, and double ICIs lead to the greatest OS benefit compared with sorafenib, whereas ICI + kinase inhibitor regimens are associated with greater PFS benefit at the cost of higher toxicity r
Openshaw MR, Gervasi E, Fulgenzi CAM, et al., 2023, Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis, Publisher: BMC, Pages: 11-11, ISSN: 1464-2662
Openshaw MR, Gervasi E, Fulgenzi CAM, et al., 2023, Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis, Journal of Translational Medicine, Vol: 21, Pages: 1-13, ISSN: 1479-5876
BACKGROUND: The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic/HIV associated and iatrogenic KS, and KS in men who have sex with men (MSM). We assessed the medical relevance of the current classification of KS and sought clinically useful improvements in KS taxonomy. METHODS: We reviewed the demographic and clinicopathological features of 676 patients with KS, who were referred to the national centre for HIV oncology at Chelsea Westminster hospital between 2000 and 2021. RESULTS: Demographic differences between the different subtypes of KS exist as tautological findings of the current classification system. However, no definitive differences in clinicopathological, virological or immunological parameters at presentation could be demonstrated between the classic, endemic or MSM KS patients. Reclassifying patients as either immunosuppressed or non-immunosuppressed, showed that the immunosuppressed group had a significantly higher proportion of adverse disease features at presentation including visceral disease and extensive oral involvement, classified together as advanced disease (chi2 P = 0.0012*) and disseminated skin involvement (chi2 P < 0.0001*). Immunosuppressed patients had lower CD4 counts, higher CD8 counts and a trend towards higher HHV8 levels compared to non-immunosuppressed patients, however overall survival and disease specific (KS) survival was similar across groups. CONCLUSION: The current system of KS classification does not reflect meaningful differences in clinicopathological presentation or disease pathogenesis. Reclassification of patients based on the presence or absence of immunosuppression is a more clinically meaningful system that may influence therapeutic approaches to KS.
Fessas P, Scheiner B, D'Alessio A, et al., 2023, PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma, FUTURE ONCOLOGY, ISSN: 1479-6694
Plummer R, Sodergren M, Ryan B, et al., 2023, MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade, 114th Annual Meeting of the American Association for Cancer Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Durrant LG, Masters F, Paston S, et al., 2023, Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical Ttial, 114th Annual Meeting of the American Association for Cancer Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Martini V, Stella A, Ben Ayed R, et al., 2023, Evaluation of extracellular vesicles (EVs) as potential predictors of response to immunotherapy (IO) in triple negative early and advanced breast cancer (BC): preliminary evidence from the IRIS project, 114th Annual Meeting of the American Association for Cancer Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Lu H, Wengert G, Lou H, et al., 2023, Tumour and local lymphoid tissue interaction determines prognosis in high grade serous ovarian cancer, 114th Annual Meeting of the American Association for Cancer Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Auclin E, Benitez-Montanez J, Tagliamento M, et al., 2023, Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer, LUNG CANCER, Vol: 178, Pages: 116-122, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 1
Makrakis D, Bakaloudi DR, Talukder R, et al., 2023, Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma, CLINICAL GENITOURINARY CANCER, Vol: 21, Pages: 286-294, ISSN: 1558-7673
- Author Web Link
- Cite
- Citations: 3
Anpalakhan S, Huddar P, Behrouzi R, et al., 2023, Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis, Publisher: ELSEVIER IRELAND LTD, Pages: S33-S33, ISSN: 0169-5002
Cortellini A, Tabernero J, Mukherjee U, et al., 2023, SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry, The Lancet Oncology, Vol: 24, Pages: 335-346, ISSN: 1213-9432
BACKGROUND: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2. METHODS: OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)-delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974. FINDINGS: At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24-68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8-18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4-22·0] of 1000 patients). The prevalence was similar in the alpha-delta phase (110 [16·8%; 13·8-20&middo
Talbot T, D'Alessio A, Pinter M, et al., 2023, Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study, International Liver Congress, Publisher: WILEY, Pages: 695-707, ISSN: 1478-3223
- Author Web Link
- Cite
- Citations: 3
van de Haar J, Ma X, Ooft SN, et al., 2023, Codon-specific <i>KRAS</i> mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer, NATURE MEDICINE, Vol: 29, Pages: 605-+, ISSN: 1078-8956
- Author Web Link
- Cite
- Citations: 11
Wu YL, van Hyfte G, Ozbek U, et al., 2023, Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors, FRONTIERS IN ONCOLOGY, Vol: 13, ISSN: 2234-943X
Pinter M, Pinato DJ, Ramadori P, et al., 2023, NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy, CLINICAL CANCER RESEARCH, Vol: 29, Pages: 513-520, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 12
Pinter M, Pinato D, 2023, Local and systemic therapy in liver cancer: the quest for synergy, LANCET GASTROENTEROLOGY & HEPATOLOGY, Vol: 8, Pages: 102-104
Scheiner B, Roessler D, Phen S, et al., 2023, Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma, Publisher: ELSEVIER, Pages: S1367-S1369, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 7
Rakaee M, Adib E, Ricciuti B, et al., 2023, Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC, JAMA ONCOLOGY, Vol: 9, Pages: 51-60, ISSN: 2374-2437
- Author Web Link
- Cite
- Citations: 17
Anpalakhan S, Huddar P, Behrouzi R, et al., 2023, The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol: 24
- Author Web Link
- Cite
- Citations: 2
Cammarota A, Zanuso V, Manfredi GF, et al., 2023, Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol: 15, ISSN: 1758-8340
- Author Web Link
- Cite
- Citations: 7
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.